1. Volume 14, Issue 1, Pages 80-89 (January 2011)
Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy 
S. Iannazzo, EngD, MBA, L. Pradelli, MD, M. Carsi, MSc, M. Perachino, MD 
Value in Health 
Volume 14, Issue 1, Pages (January 2011)
DOI: /j.jval
Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1
Simplified structure of the model, represented as a decisional tree, with evaluated treatment options. In each branch, the simulation is conducted using a Markov chain. For simplicity, only the leuprorelin 22.5-mg branch is fully represented. pCancerDeath, probability of cancer-related death; pDeath, probability of death; pProgression, probability of disease progression.
Value in Health  , 80-89DOI: ( /j.jval )
Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3. Fig. 2
Comparative cost-effectiveness of five LHRH agonist formulations in the treatment of metastatic prostate cancer. In this representation, the higher the slope, the more cost-effective the treatment: better clinical results are obtained at the same cost.
Value in Health  , 80-89DOI: ( /j.jval )
Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

4. Fig. 3
Scatterplot of the 1000 incremental cost-effectiveness ratio (ICER) estimates for buserelin versus leuprorelin 22.5 mg in the probabilistic sensitivity analysis. ♢ shows the mean value of the cost-effectiveness ratio. NE, northeast; SE, southeast.
Value in Health  , 80-89DOI: ( /j.jval )
Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

5. Fig. 4
Incremental cost-effectiveness acceptability curve for buserelin versus leuprorelin 22.5 mg in the treatment of metastatic prostate cancer.
Value in Health  , 80-89DOI: ( /j.jval )
Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions